Creighton University's Hereditary Cancer Institute (CU), in three decades of study of hereditary cancer syndromes, has amassed a large resource of hereditary cancer families. We have the rapport with family members and the research experience to recruit members of these families for biomarker research. We have a large collection of biological specimens with extensive linked clinical and pedigree data. We will use these resources in collaborative biomarker research as a Clinical Epidemiology and Validation Center of the Early Detection Research Network (EDRN). As a member of the Network, our objectives will be: 1. To support EDRN collaborative studies by a. recruiting members of cancer-prone families for participation b. supplying specimens and associated data from our specimen repository 2. To maintain and expand our registry of individuals at high risk of specific cancer types who are willing to participate in biomarker studies. We will enroll individuals who are carriers of hereditary cancer syndrome associated germ-line mutations. 3. To develop a serum repository with annual samples recruited from high risk individuals. 4. To serve as a resource on hereditary cancer syndromes for other EDRN investigators. 5. To carry out the following research projects a. a study of the frequency of CDKN2A, MGMT, HLTF, APC, HIC1, p14 ARF, MINT31, MINT2, TIMP3, THBS1, and MLH1 methylation in Lynch syndrome colon adenomas and early colorectal cancers, and of the value of methylation assays of stool or serum DNA for detecting early methylation-positive colon neoplasms in Lynch syndrome patients. b. a study to evaluate the acceptability of hypothetical biomarkers among high risk and average risk individuals and primary health care providers.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRRB-E (J1))
Program Officer
Wagner, Paul D
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Creighton University
Public Health & Prev Medicine
Schools of Medicine
United States
Zip Code
Skates, Steven J; Greene, Mark H; Buys, Saundra S et al. (2017) Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials. Clin Cancer Res 23:3628-3637
Neuhausen, Susan L; Brummel, Sean; Ding, Yuan Chun et al. (2011) Genetic variation in IGF2 and HTRA1 and breast cancer risk among BRCA1 and BRCA2 carriers. Cancer Epidemiol Biomarkers Prev 20:1690-702
Rebbeck, Timothy R; Mitra, Nandita; Domchek, Susan M et al. (2011) Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1-Interacting Genes. Cancer Res 71:5792-805
Spurdle, Amanda B; Marquart, Louise; McGuffog, Lesley et al. (2011) Common genetic variation at BARD1 is not associated with breast cancer risk in BRCA1 or BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev 20:1032-8
Drescher, Kristen M; Sharma, Poonam; Lynch, Henry T (2010) Current hypotheses on how microsatellite instability leads to enhanced survival of Lynch Syndrome patients. Clin Dev Immunol 2010:170432
Lynch, Henry T; Lynch, Jane F (2010) Hereditary diffuse gastric cancer: lifesaving total gastrectomy for CDH1 mutation carriers. J Med Genet 47:433-5
Nabilsi, Nancy H; Broaddus, Russell R; McCampbell, Adrienne S et al. (2010) Sex hormone regulation of survivin gene expression. J Endocrinol 207:237-43
Lynch, Henry T; Snyder, Carrie L; Lynch, Jane F et al. (2009) Family information service participation increases the rates of mutation testing among members of families with BRCA1/2 mutations. Breast J 15 Suppl 1:S20-4
Lynch, Henry T; Snyder, Carrie L; Lynch, Jane F (2009) Genetic counseling and the advanced practice oncology nursing role in a hereditary cancer prevention clinic: hereditary breast cancer focus (part II). Breast J 15 Suppl 1:S11-9
Drescher, Kristen M; Sharma, Poonam; Watson, Patrice et al. (2009) Lymphocyte recruitment into the tumor site is altered in patients with MSI-H colon cancer. Fam Cancer 8:231-9

Showing the most recent 10 out of 84 publications